Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of CM24 combined with nivolumab in adults with advanced solid tumors
MOH_2021-05-19_009981Phase 2Recruiting
- Sponsor
- FameWave
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cm-24 and nivolumab in non-small cell lung cancer (NSCLC), colorectal adenocarcinoma, melanoma and 4 more (3 arms), sponsored by FameWave. Primary endpoints: Safety and tolerability, Recommended phase 2 dose and 1 more. Started Mar 2021; status: recruiting.
02
Drugs
cm-24nivolumab
03
Conditions
non-small cell lung cancer (NSCLC)colorectal adenocarcinomamelanomaovarian cancerpapillary thyroid cancer (PTC)
Beyond the preview
Go deeper on MOH_2021-05-19_009981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-19_009981.